Table 3.
Comorbidity profiles among analyzed population
| Comorbidity | ICD10 | Total population with fracture treatment cost > 0 | |||
|---|---|---|---|---|---|
| Male | Female | ||||
| n = 2143 (%) | n = 10,755 (%) | ||||
| GI diseasesa | K21,K25, K29 | 1498 | (70%) | 7165 | (67%) |
| Hypertension | I10-I15 | 1200 | (56%) | 5567 | (52%) |
| Other functional intestinal disorder | K59 | 1018 | (47%) | 4389 | (41%) |
| Dorsalgia | M54 | 834 | (39%) | 3846 | (36%) |
| Disorders of lipoprotein metabolism and other lipidemia | E78 | 585 | (27%) | 3649 | (34%) |
| Sleep disorders | G47 | 649 | (30%) | 3406 | (32%) |
| Diabetes | E10-E14 | 743 | (35%) | 2853 | (27%) |
| Osteoarthritis of knee | M17 | 260 | (12%) | 2689 | (25%) |
| Angina pectoris | I20 | 486 | (23%) | 1855 | (17%) |
| Heart failure | I50 | 496 | (23%) | 1801 | (17%) |
| Disorder of refraction and accommodation | H52 | 362 | (17%) | 1776 | (17%) |
| Iron deficiency anemia | D50 | 359 | (17%) | 1554 | (14%) |
| COPD | J40–44, J47 | 402 | (19%) | 1127 | (10%) |
| Chronic kidney disease | N18 | 241 | (11%) | 396 | (4%) |
| Thyrotoxicosis | E05 | 28 | (1%) | 172 | (2%) |
| Hypofunction and other disorders of the pituitary gland | E23 | 9 | (0.42%) | 24 | (0.22%) |
| Primary hyperparathyroidism | E210 | 2 | (0.09%) | 7 | (0.07%) |
| Cushing’s syndrome | E24 | 0 | (0%) | 4 | (0.04%) |
aGastrointestinal (GI) diseases includes gastro-esophageal reflux disease, gastric ulcer, gastritis, and duodenitis